4 h. ago Novo Nordisk shares shoot up amid promising results for anti

Stock climbs above £6.5bn in early trading as trial shows ‘significant weight loss’ for pill version of WegovyBusiness live – latest updatesThe value of the drugmaker Novo Nordisk has shot up by more than £6.5bn after research showed its new anti-obesity pill resulted in almost as much weight loss as its Wegovy jab, as it races against its US rival Eli Lilly to get a tablet treatment to market.Stock in the Danish company climbed by more than 4.5% on Thursday morning on hopes it could claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. Shares have fallen nearly 60% in the past year as sales slowed. Continue reading...

Events

34 h. ago Novo Nordisk’s new boss wins cautious backing after sweeping cuts

Maziar Mike Doustdar has an onerous in-tray to stop the company falling behind in the lucrative US obesity market

Politics

3 d. ago Triple dose of Novo Nordisk drug delivers 19% weight loss in trials

Danish pharma group seeks to broaden options and stay competitive with Eli Lilly

Events

8 d. ago Ozempic maker to slash 9,000 jobs globally as competition intensifies

Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed.

Politics

8 d. ago Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

Economics

8 d. ago Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly Business live – latest newsThe Danish maker of the weight-loss drug Wegovy and diabetes drug Ozempic is to cut 9,000 jobs as it issued a profit warning amid fierce competition from its US rival Eli Lilly.Novo Nordisk’s decision to cut 11% of its global workforce of 78,400 takes place as sales of Wegovy have slowed sharply as it has lost ground to Eli Lilly’s Mounjaro jabs, as well as cheaper versions by generic drugmakers, and the pharmaceutical sector faces the threat of targeted US tariffs. Continue reading...

Politics

8 d. ago Novo Nordisk to cut 9,000 jobs as it slashes profit forecast

Danish drugmaker warns over slowing growth as Ozempic and Wegovy producer faces pressure from US rival Eli Lilly

Politics

8 d. ago Ozempic maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly Business live – latest newsThe maker of the weight-loss and diabetes drugs Ozempic and Wegovy is to cut 9,000 jobs as it issued a profit warning amid increased competition from the US rival Eli Lilly.Novo Nordisk’s decision to cut 11% of its global workforce comes as sales of its diabetes drugs including Ozempic have slowed sharply as it faces fierce competition from Eli Lilly’s Mounjaro jabs and the threat of US tariffs. Continue reading...

Politics

2 w. ago Starmer criticises Reform and Tory ‘scaremongering’ as MPs return to Westminster

Sir Keir has promised a ‘national renewal’ after a summer of anti-migrant protests and troubling Labour poll ratings

Politics

3 w. ago Poland’s president vetoes legislation to prolong benefits for Ukrainian refugees

Karol Nawrocki says only Ukrainians in work should receive child benefit payments in PolandPoland’s president has vetoed legislation to prolong benefits received by Ukrainian refugees in Poland, following up on a campaign promise to tighten welfare payments amid a steady growth in anti-Ukrainian sentiment among Poles.Karol Nawrocki, who took office earlier this month after winning an election in spring, said only Ukrainians in work should receive child benefit payments. Continue reading...

Politics